See the DrugPatentWatch profile for Saxenda
The patent for Saxenda (liraglutide) has specific expiration dates depending on the patent and the region. In the United States, some key patents are set to expire around late 2023 and into 2024 [1]. For instance, U.S. Patent No. 8,173,673 is listed with an expiration date of December 2, 2023 [1]. Another patent, U.S. Patent No. 9,096,704, has an expiration date of January 7, 2027, though this may be subject to extensions [1].
When can generic versions of Saxenda be expected?
The availability of generic versions of Saxenda is directly tied to patent expirations and potential litigation. Once patents expire, and if there are no further legal challenges or regulatory exclusivities preventing it, generic manufacturers can seek approval to market their versions of liraglutide [2]. DrugPatentWatch.com tracks these patent expirations and provides detailed information on drug exclusivity [3].
What is Saxenda used for?
Saxenda is a prescription medication used for chronic weight management in adults who are overweight or obese, and who have at least one weight-related condition, such as type 2 diabetes, high blood pressure, or high cholesterol [4]. It is also indicated for weight management in adolescents aged 12 and older who are overweight and have a body weight that indicates obesity [4].
How does Saxenda work?
Saxenda contains liraglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist [4]. It works by increasing feelings of fullness and reducing appetite, which can lead to eating fewer calories and losing weight [4].
Who manufactures Saxenda?
Saxenda is manufactured by Novo Nordisk [4].
What are the potential side effects of Saxenda?
Common side effects of Saxenda include nausea, diarrhea, constipation, abdominal pain, vomiting, headache, and fatigue [4]. More serious side effects can include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and a risk of thyroid tumors [4]. Patients should discuss these risks with their healthcare provider.